300485 Beijing Science Sun Pharmaceutical Co.,Ltd.
Closed 04-02 15:00:00
11.72
+0.36
+3.17%
High12.15Low11.19Vol31.83M
Open11.30D1 Closing11.36Amplitude8.45%
Mkt Cap5.65BTradable Cap3.21BTotal Shares482.00M
T/O375.00MT/O Rate11.62%Tradable Shares274.00M
P/B1.62ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Novo Nordisk cuts Ozempic, Wegovy prices in India again to fight cheaper generics
Reuters  ·  03-31 19:21
Novo Nordisk cuts Ozempic, Wegovy prices in India again to fight cheaper generics
Beijing Science Sun Pharmaceutical Turns Profit in 2025, Reports Net Income of 14.571 Million Yuan
Stock News  ·  03-30
Beijing Science Sun Pharmaceutical Turns Profit in 2025, Reports Net Income of 14.571 Million Yuan
Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
Reuters  ·  03-28
Sun Pharma Says Partner Philogen's Phase II Flash Study In Soft Tissue Sarcoma Did Not Meet Primary Endpoint
BUZZ-India's hospitals, drugmakers set for weekly gains on steady earnings outlook, GLP-1 scope
Reuters  ·  03-27
BUZZ-India's hospitals, drugmakers set for weekly gains on steady earnings outlook, GLP-1 scope
BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity
Reuters  ·  03-25
BUZZ-UBS initiates Indian pharma coverage amid weight-loss drug opportunity
Beijing Science Sun Pharmaceutical's Subsidiary Withdraws Drug Registration Application
Stock News  ·  03-20
Beijing Science Sun Pharmaceutical's Subsidiary Withdraws Drug Registration Application
Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis
Reuters  ·  03-16
Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis
PTAB Invalidates Sun Pharma Patent Claims in Biofrontera Dispute
Reuters  ·  02-26
PTAB Invalidates Sun Pharma Patent Claims in Biofrontera Dispute
Biocon aims for revenue surge with rollout of generic weight-loss drugs
Reuters  ·  02-13
Biocon aims for revenue surge with rollout of generic weight-loss drugs
BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US
Reuters  ·  01-23
BUZZ-PREVIEW-India's Cipla climbs; analysts upbeat on domestic earnings, cautious on US
Indian drugmakers get regulatory nod to sell generic Wegovy, heating obesity‑drug race
Reuters  ·  01-23
Indian drugmakers get regulatory nod to sell generic Wegovy, heating obesity‑drug race
BREAKINGVIEWS-India sets the stage for US obesity price war
Reuters  ·  01-09
BREAKINGVIEWS-India sets the stage for US obesity price war
Beijing Science Sun Pharmaceutical (300485.SZ) Receives Acceptance for Dapagliflozin and Metformin Extended-Release Tablets Drug Registration Application
Stock News  ·  2025-12-04
Beijing Science Sun Pharmaceutical (300485.SZ) Receives Acceptance for Dapagliflozin and Metformin Extended-Release Tablets Drug Registration Application

Introduction

Company Name.
北京赛升药业股份有限公司
Industry:
医药制造业
Listing Date:
2015-06-26
Main Business:
　　北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。
Issue price:
38.46